PMC:7558914 / 14884-16038 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T21","span":{"begin":465,"end":472},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T22","span":{"begin":465,"end":472},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T23","span":{"begin":529,"end":536},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T24","span":{"begin":529,"end":536},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"}],"text":"This study showed that the COVID-19 protocols of the largest hospitals in Andalusia (Spain) varied widely in several aspects, including antiviral treatment: they used different dosages, durations, and combinations of treatment for the same clinical condition. Corticosteroid and anakinra regimens varied among hospitals, whereas tocilizumab was uniform across all protocols. Although anticoagulant treatment was recommended in all protocols, including prophylactic heparin during hospitalization for all patients and therapeutic heparin for patients with evidence of venous thromboembolism, only a few protocols included higher prophylactic doses for patients at high risk of thrombosis and therapeutic doses for patients in critical condition or who experience a progressive increase in D-dimer levels. On the other hand, all treatment protocols included the same patient groups, defined according to the clinical situation, symptomatic treatment and recommendations for infection prevention and control, supportive care and hospital organization, equivalent empirical antibacterial agents, drug warnings and interactions, and discharge recommendations."}

{"project":"LitCovid-PubTator","denotations":[{"id":"359","span":{"begin":504,"end":512},"obj":"Species"},{"id":"360","span":{"begin":541,"end":549},"obj":"Species"},{"id":"361","span":{"begin":651,"end":659},"obj":"Species"},{"id":"362","span":{"begin":713,"end":721},"obj":"Species"},{"id":"363","span":{"begin":865,"end":872},"obj":"Species"},{"id":"364","span":{"begin":329,"end":340},"obj":"Chemical"},{"id":"365","span":{"begin":465,"end":472},"obj":"Chemical"},{"id":"366","span":{"begin":529,"end":536},"obj":"Chemical"},{"id":"367","span":{"begin":27,"end":35},"obj":"Disease"},{"id":"368","span":{"begin":74,"end":83},"obj":"Disease"},{"id":"369","span":{"begin":567,"end":589},"obj":"Disease"},{"id":"370","span":{"begin":676,"end":686},"obj":"Disease"},{"id":"371","span":{"begin":972,"end":981},"obj":"Disease"}],"attributes":[{"id":"A359","pred":"tao:has_database_id","subj":"359","obj":"Tax:9606"},{"id":"A360","pred":"tao:has_database_id","subj":"360","obj":"Tax:9606"},{"id":"A361","pred":"tao:has_database_id","subj":"361","obj":"Tax:9606"},{"id":"A362","pred":"tao:has_database_id","subj":"362","obj":"Tax:9606"},{"id":"A363","pred":"tao:has_database_id","subj":"363","obj":"Tax:9606"},{"id":"A364","pred":"tao:has_database_id","subj":"364","obj":"MESH:C502936"},{"id":"A365","pred":"tao:has_database_id","subj":"365","obj":"MESH:D006493"},{"id":"A366","pred":"tao:has_database_id","subj":"366","obj":"MESH:D006493"},{"id":"A367","pred":"tao:has_database_id","subj":"367","obj":"MESH:C000657245"},{"id":"A369","pred":"tao:has_database_id","subj":"369","obj":"MESH:D054556"},{"id":"A370","pred":"tao:has_database_id","subj":"370","obj":"MESH:D013927"},{"id":"A371","pred":"tao:has_database_id","subj":"371","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"This study showed that the COVID-19 protocols of the largest hospitals in Andalusia (Spain) varied widely in several aspects, including antiviral treatment: they used different dosages, durations, and combinations of treatment for the same clinical condition. Corticosteroid and anakinra regimens varied among hospitals, whereas tocilizumab was uniform across all protocols. Although anticoagulant treatment was recommended in all protocols, including prophylactic heparin during hospitalization for all patients and therapeutic heparin for patients with evidence of venous thromboembolism, only a few protocols included higher prophylactic doses for patients at high risk of thrombosis and therapeutic doses for patients in critical condition or who experience a progressive increase in D-dimer levels. On the other hand, all treatment protocols included the same patient groups, defined according to the clinical situation, symptomatic treatment and recommendations for infection prevention and control, supportive care and hospital organization, equivalent empirical antibacterial agents, drug warnings and interactions, and discharge recommendations."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T27","span":{"begin":574,"end":589},"obj":"Phenotype"}],"attributes":[{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0001907"}],"text":"This study showed that the COVID-19 protocols of the largest hospitals in Andalusia (Spain) varied widely in several aspects, including antiviral treatment: they used different dosages, durations, and combinations of treatment for the same clinical condition. Corticosteroid and anakinra regimens varied among hospitals, whereas tocilizumab was uniform across all protocols. Although anticoagulant treatment was recommended in all protocols, including prophylactic heparin during hospitalization for all patients and therapeutic heparin for patients with evidence of venous thromboembolism, only a few protocols included higher prophylactic doses for patients at high risk of thrombosis and therapeutic doses for patients in critical condition or who experience a progressive increase in D-dimer levels. On the other hand, all treatment protocols included the same patient groups, defined according to the clinical situation, symptomatic treatment and recommendations for infection prevention and control, supportive care and hospital organization, equivalent empirical antibacterial agents, drug warnings and interactions, and discharge recommendations."}

{"project":"LitCovid-sentences","denotations":[{"id":"T103","span":{"begin":0,"end":259},"obj":"Sentence"},{"id":"T104","span":{"begin":260,"end":374},"obj":"Sentence"},{"id":"T105","span":{"begin":375,"end":803},"obj":"Sentence"},{"id":"T106","span":{"begin":804,"end":1154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"This study showed that the COVID-19 protocols of the largest hospitals in Andalusia (Spain) varied widely in several aspects, including antiviral treatment: they used different dosages, durations, and combinations of treatment for the same clinical condition. Corticosteroid and anakinra regimens varied among hospitals, whereas tocilizumab was uniform across all protocols. Although anticoagulant treatment was recommended in all protocols, including prophylactic heparin during hospitalization for all patients and therapeutic heparin for patients with evidence of venous thromboembolism, only a few protocols included higher prophylactic doses for patients at high risk of thrombosis and therapeutic doses for patients in critical condition or who experience a progressive increase in D-dimer levels. On the other hand, all treatment protocols included the same patient groups, defined according to the clinical situation, symptomatic treatment and recommendations for infection prevention and control, supportive care and hospital organization, equivalent empirical antibacterial agents, drug warnings and interactions, and discharge recommendations."}